| World Journal of Oncology, ISSN 1920-4531 print, 1920-454X online, Open Access |
| Article copyright, the authors; Journal compilation copyright, World J Oncol and Elmer Press Inc |
| Journal website https://www.wjon.org |
Review
Volume 14, Number 1, February 2023, pages 26-31
Postoperative Chemotherapy After Surgical Resection of Metachronous Metastases of Colorectal Cancer: A Systematic Review
Table
| Author/year | Country | Chemotherapy regimen | Number of patients | RFS (ACT vs. surgery only) | OS (ACT vs. surgery only) |
|---|---|---|---|---|---|
| ACT: adjuvant chemotherapy; 5-FU: 5-fluorouracil; FOLFOX: oxaliplatin, leucovorin, fluorouracil; OS: overall survival; RFS: relapse-free survival; FOLFIRI: irinotecan, leucovorin, fluorouracil; HR: hazard ratio; CI: confidence interval. | |||||
| Park et al, 2015 [14] | Korea | 1) Monofluoropyrimidines (5-FU, TS-1, or capecitabine) | 221 | 32.7 vs. 11.20 months, P = 0.076 | 89.6 vs. 86.8 months, P = 0.833 |
| 2) FOLFOX | |||||
| 3) FOLFIRI | |||||
| Imanishi et al, 2019 [15] | Japan | 1) Monofluoropyrimidines | 384 | 2.1 vs. 2.2 years (HR: 1.07; 95% CI: 0.82 - 1.39; P = 0.62) | 8 years and not reached in the surgery alone group (HR: 1.00; 95% CI: 0.69 - 1.45; P = 1.00) |
| 2) FOLFOX | |||||
| 3) FOLFIRI | |||||
| Zhang et al, 2019 [16] | China | 1) Monofluoropyrimidines | 3,885 | HR: 0.91; 95% CI: 0.74 - 1.11; P = 0.339 | HR: 0.78; 95% CI: 0.60 - 1.03; P = 0.077 |
| 2) Fluoropyrimidine with leucovorin | |||||
| 3) FOLFOX | |||||
| 4) FOLFIRI | |||||
| Mauri et al, 2018 [17] | Greece | Monofluoropyrimidines | 482 | HR: 0.645, 95% CI: 0.509 - 0.818, P = 0.001 | HR: 0.781, 95% CI: 0.593 - 1.030, P = 0.080 |
| Kanemitsu et al, 2021 [18] | Japan | FOLFOX | 300 | 5-year RFS 49.8% vs. 38.7%, P = 0.006 | 5-year OS 71.2% vs. 83.1% (HR: 1.25; 95% CI: 0.78 - 2.00; two-sided P = 0.42) |
| Ciliberto et al, 2012 [19] | Italy | FOLFOX, FOLFIRI | 642 | HR: 0.75; 95% CI: 0.620 - 0.910; P = 0.003 | HR: 0.743; 95% CI: 0.527 - 1.045; P = 0.088 |
| Wang et al, 2015 [20] | China | 5-FU, FOLFOX, hepatic arterial infusion, regional Chemotherapy in combination with systemic Chemotherapy | 1,896 | HR: 0.81; 95% CI: 0.72 - 0.91; P = 0.0007 | HR: 0.88; 95% CI: 0.77 - 1.01; P = 0.07 |
| Araujo et al, 2015 [21] | Brazil | 5-FU, FOLFOX | 2,475 | HR: 0.71; 95% CI: 0.61 - 0.83; P < 0.001 | HR: 0.77; 95% CI: 0.67 - 0.88; P < 0.001 |